Raúl G. Saraiva, Phd

LiMM is the biopharmaceutical company harnessing the molecular cross-talk between neuronal and innate lymphoid cells within peripheral tissues. By decoding the language of the neuroimmune cross-talk, we are developing first-in-class therapeutic products – NRILs: neuronal reprogrammers of innate lymphocytes - to preserve health and treat inflammatory, infectious and metabolic diseases. We are bridging neural sensing and immunology discoveries to unlock therapeutic solutions for the benefit of patients.

Immunethep is a biotech startup company (spin-off from the University of Porto) that is developing anti-bacterial immunotherapies based on the discovery of a virulence mechanism shared by different bacteria that cause life-threatening infections. We are working on preventing and treating infectious diseases to improve global health (SDG#3) for a safer tomorrow free of AntiMicrobial Resistance (AMR). We will accomplish our mission by developing anti-infective immunotherapies that potentiate a natural and strong immune response from the infected host, reducing the disease burden and mortality rates.

3xP Global We stand for People, Planet, Prosperity. 3XP Global is an Asset Management firm that aggregates a unique track record in terms of ESG Integration in the Investment Process and Active Role by supporting founders during the all life of the investments cycle. Sustainability Best Practices for Sustainable Investments are our Ethos! Being the first financial company as a B Corp in Portugal, 3xP Global has the 17 United Nations SDG’s (Sustainable Development Goals) as key core values, sustained by the idea that along with sustainability comes return. We are UN PRI signatories and follow the GRI Standards Reporting. 3XP Global invests in companies whose sustainable trends and practices create real value for investors while contributing to a more Sustainable EARTH. Regulated and supervised by Portuguese Securities Market Commission (CMVM), 3XP Global ensures full Transparency, Integrity and Independence. We are fully committed to lead all investments to increase companies sustainability levels into business models. Therefore, 3XP Global provides the leading platform Grow Sustainable connecting founders to international markets, from Europe to Asia and America.

Founded in 1999, ATP is a leader in life sciences venture capital.  ATP creates companies starting at various stages, from pre-IP ideas to asset spinouts, investing in them from seed stage through IPO and beyond.  The core of ATP’s strategy is to provide flexible capital and access to a world-class team of venture partners and EIRs, to build sustainable, research-driven enterprises that improve human lives.  For more information, visit www.appletreepartners.com.

LiMM is the biopharmaceutical company harnessing the molecular cross-talk between neuronal and innate lymphoid cells within peripheral tissues. By decoding the language of the neuroimmune cross-talk, we are developing first-in-class therapeutic products – NRILs: neuronal reprogrammers of innate lymphocytes - to preserve health and treat inflammatory, infectious and metabolic diseases. We are bridging neural sensing and immunology discoveries to unlock therapeutic solutions for the benefit of patients.

We are a Contract Development and Manufacturing Organisation (CDMO) focused on regenerative medicine. Our company addresses product/process development and current Good Manufacturing Practice (cGMP) production and clinical translation of impactful medicinal products. Stemmatters´ core expertise addresses multiple investigational medicinal products (IMPs), including advanced therapy medicinal products (ATMPs), biologicals, and diverse raw materials supporting the product life cycle of innovative therapeutic products.